• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ZIVO Bioscience to Present at The Microcap Conference 2025

    1/22/25 4:15:00 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZIVO alert in real time by email

    Zivo Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.

    Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.

    Event: The Microcap Conference 2025

    Location: Studio 1, Borgata Hotel Casino & Spa

    Date: Thursday January 30, 2025

    Time: 2:30 PM Eastern Time

    Investors interested in meeting with management can register for the conference here.

    About ZIVO Bioscience

    Zivo Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250122415215/en/

    ZIVO Bioscience

    Keith Marchiando, Chief Financial Officer

    (248) 452-9866 x130

    [email protected]



    Alliance Advisors IR

    Tirth T. Patel

    (212) 201-6614

    [email protected]

    Get the next $ZIVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZIVO

    DatePrice TargetRatingAnalyst
    12/15/2021$9.00Buy
    Maxim Group
    More analyst ratings

    $ZIVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

      ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirm

      5/6/25 5:54:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

      ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. ZIVO's previous study with the University of Delaware demonstrated a significant reduction in viral shedding and a delay in disease transmission among treated birds. This new study is designed to further optimize formul

      2/6/25 4:36:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZIVO Bioscience to Present at The Microcap Conference 2025

      Zivo Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J. Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities. Event: The Microcap Conference 2025 Location: Studio 1, Borgata Hotel Casino & Spa Date: Thursday January 30, 2025 Time: 2:30 PM Eastern Time Investors i

      1/22/25 4:15:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Zivo Bioscience with a new price target

      Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00

      12/15/21 10:56:47 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Zivo Bioscience Inc.

      SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)

      10/1/24 2:57:20 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Zivo Bioscience Inc.

      SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

      6/12/24 8:49:08 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Zivo Bioscience Inc.

      SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

      6/12/24 8:44:12 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yaldoo Laith L bought $176,682 worth of shares (10,080 units at $17.53) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/4/25 8:23:32 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Strome Mark E bought $1,514,250 worth of shares (75,000 units at $20.19) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      12/31/24 6:47:29 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yaldoo Laith L bought $49,993 worth of shares (3,133 units at $15.96) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      10/17/24 7:33:33 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Zivo Bioscience Inc.

      DEF 14A - Zivo Bioscience, Inc. (0001101026) (Filer)

      4/25/25 4:36:25 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Zivo Bioscience Inc.

      DEFA14A - Zivo Bioscience, Inc. (0001101026) (Filer)

      4/25/25 8:30:43 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Zivo Bioscience Inc.

      10-K - Zivo Bioscience, Inc. (0001101026) (Filer)

      3/18/25 4:10:47 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Maggiore Christopher D. sold $325 worth of shares (20 units at $16.25), decreasing direct ownership by 0.00% to 507,000 units (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/9/25 9:42:34 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yaldoo Laith L bought $176,682 worth of shares (10,080 units at $17.53) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/4/25 8:23:32 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 5 filed by Strome Mark E

      5 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      1/23/25 7:48:25 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Financials

    Live finance-specific insights

    See more
    • ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business

      ZIVOLife to be Granted Exclusive Worldwide Limited License to ZIVO Bioscience Intellectual Property for the Production and Supply of Whole Biomass Algal Products Conference call to be held in early November Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company's corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company's prop

      10/24/22 4:15:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care